Companies › Viridian Therapeutics
1 active drug program in 3 registered trials: 3 Phase 3; Ophthalmology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| VRDN-003 Humanized monoclonal antibody directed against insulin-like growth factor-1 receptor (IGF- | IGF1R | Phase 3 | Thyroid Eye Disease (TED); Thyroid Eye Disease | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06812325 | VRDN-003 | Phase 3 | Thyroid Eye Disease (TED) | Ophthalmology | Apr 2026 |
| NCT06625411 | VRDN-003 | Phase 3 | Thyroid Eye Disease | Ophthalmology | Nov 2026 |
| NCT06625398 | VRDN-003 | Phase 3 | Thyroid Eye Disease | Ophthalmology | Dec 2026 |
Held by 12 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Innovent Biologics (Suzhou) OHB Neonatology Amgen Candid Therapeutics Minghui Pharmaceutical (Hangzhou) Sling Therapeutics Zai Lab (Shanghai)
Cloudbreak Therapeutics Omikron Italia S.r.l. Aurion Biotech Smilebiotek Zhuhai Beletalent (Zhuhai) Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.